These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 35758639)
1. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. Paul SM; Yohn SE; Popiolek M; Miller AC; Felder CC Am J Psychiatry; 2022 Sep; 179(9):611-627. PubMed ID: 35758639 [TBL] [Abstract][Full Text] [Related]
5. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Conn PJ; Jones CK; Lindsley CW Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489 [TBL] [Abstract][Full Text] [Related]
6. Muscarinic Receptor Activators as Novel Treatments for Schizophrenia. Paul SM; Yohn SE; Brannan SK; Neugebauer NM; Breier A Biol Psychiatry; 2024 Oct; 96(8):627-637. PubMed ID: 38537670 [TBL] [Abstract][Full Text] [Related]
7. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. Mirza NR; Peters D; Sparks RG CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557 [TBL] [Abstract][Full Text] [Related]
8. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Barak S; Weiner I Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109 [TBL] [Abstract][Full Text] [Related]
9. Biased Profile of Xanomeline at the Recombinant Human M McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782 [TBL] [Abstract][Full Text] [Related]
14. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Dean B Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751 [TBL] [Abstract][Full Text] [Related]
15. Muscarinic acetylcholine receptors as CNS drug targets. Langmead CJ; Watson J; Reavill C Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893 [TBL] [Abstract][Full Text] [Related]
16. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348 [TBL] [Abstract][Full Text] [Related]
17. Muscarinic receptors as a target for drugs treating schizophrenia. Bymaster FP; Felder C; Ahmed S; McKinzie D Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):163-81. PubMed ID: 12769625 [TBL] [Abstract][Full Text] [Related]
18. Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders. Moran SP; Maksymetz J; Conn PJ Trends Pharmacol Sci; 2019 Dec; 40(12):1006-1020. PubMed ID: 31711626 [TBL] [Abstract][Full Text] [Related]
19. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment. Azargoonjahromi A Clin Drug Investig; 2024 Jul; 44(7):471-493. PubMed ID: 38904739 [TBL] [Abstract][Full Text] [Related]
20. Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Bubser M; Byun N; Wood MR; Jones CK Handb Exp Pharmacol; 2012; (208):121-66. PubMed ID: 22222698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]